Promopharm stock gains 2.65% in illiquid trading week

Promopharm stock gained 2.65% in the week ended Friday, October 30, according to TelQuel. The shares moved to 1,432 Moroccan dirhams from 1,395 dirhams after one transaction involving two shares on Tuesday, October 27.

The trade lifted the reference price and implied market value to about 1.43 billion Moroccan dirhams. TelQuel described Promopharm as the least liquid stock in the healthcare segment, with the reference price dependent on the next effective transaction.

One trade drives the weekly move

The trading pattern limits how much investors can infer from the weekly gain. A single deal worth 2,864 Moroccan dirhams set the latest reference point, while the lack of regular turnover leaves price discovery vulnerable to isolated transactions.

The broader healthcare segment weakened during the same week, with four of the five covered stocks declining. TelQuel reported that the sector's combined market value fell 5.05% over the week, while the planned arrival of Laprophan emerged as the main structural development for the group.

Morocco's pharmaceutical market expands

Laprophan's subscription period runs from November 9 to November 17, 2026, and its planned listing is expected to broaden the Moroccan pharmaceutical market. The new issue would add another listed drugmaker alongside Promopharm and Sothema, increasing the number of sector investment options.

Promopharm's operating position

Promopharm is Hikma's Moroccan legal entity and manufactures and markets medicines in Morocco. Its operations include two manufacturing plants focused on general formulations and penicillin, as well as products from pharmaceutical partners. Within Morocco's pharmaceutical market, Sothema is an established listed peer, while Laprophan is preparing to join the listed sector; Promopharm's distinguishing position is its Hikma-backed local manufacturing and distribution platform.